Rifaximin Treatment of Moderate to Severe Papulopustular Rosacea: Double-Blinded, Placebo-Controlled, Crossover Study

Investigator: Martin Steinhoff, MD, PhD
Sponsor: Salix Pharmaceuticals, Inc.

Location(s): United States


This is a double‐blind, crossover,  placebo‐controlled study that will randomize patients with papulopustular rosacea to either the 14‐day therapy with one tablet of rifaximin 550 mg three times a day (1650 mg/day), or the 14‐day therapy with one tablet of placebo three times a day, followed by the alternative therapy. There will be a 4‐week washout period between  rifaximin/placebo and placebo/rifaximin therapies.

100 patients will be randomized into two groups. Group A will receive one rifaximin 550 mg tablet three times a day (1650 mg/day) for 14 days, and after a 4-week washout period, receive one placebo tablet three times a day for 14 days. Group B will receive placebo first, and then rifaximin with the same dosage schedule to Group A. Assessments will be performed before application and 4 weeks after the last dosage, for both of rifaximin and placebo.